These findings suggest that miRNA-323-3p likely underlies RasGRF1 reduction after CCH, providing a novel mechanism for RasGRF1 regulation and a potential therapeutic target for cognitive dysfunction after CCH. The gene discussed is RASGRF1; the disease is columnar cell hyperplasia of the breast.